Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection.

ABSTRACT:

Objective

Adoptive immunotherapy with ex vivo expanded tumor-specific T cells has potential as anticancer therapy. Preferentially expressed antigen in melanoma (PRAME) is an attractive target overexpressed in several cancers including melanoma and acute myeloid leukaemia (AML), with low expression in normal tissue outside the gonads. We developed a GMP-compliant manufacturing method for PRAME-specific T cells from healthy donors for adoptive immunotherapy.

Methods

Mononuclear cells were pulsed with PRAME 15-mer overlapping peptide mix. After 16 h, activated cells expressing CD137 were isolated with immunomagnetic beads and cocultured with irradiated CD137^neg fraction in medium supplemented with interleukin (IL)-2, IL-7 and IL-15. Cultured T cells were resti

SUBMITTER: Lee KH 

PROVIDER: S-EPMC7577233 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature